Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis

Simple item page
dc.contributor.authorManji, Jamil
dc.contributor.authorSingh, Gurkaran
dc.contributor.authorOkpaleke, Christopher
dc.contributor.authorDadgostar, Anali
dc.contributor.authorAl-Asousi, Fahad
dc.contributor.authorAmanian, Ameen
dc.contributor.authorMacias-Valle, Luis
dc.contributor.authorFinkelstein, Andres
dc.contributor.authorTacey, Mark
dc.contributor.authorThamboo, Andrew
dc.contributor.authorJaver, Amin
dc.date.accessioned2017-10-05T14:36:25Z
dc.date.available2017-10-05T14:36:25Z
dc.date.issued2017
dc.description.abstractBACKGROUND: Although short-term use (≤2 months) of atomized topical nasal steroids has been shown to be safe and effective, the long-term safety has yet to be demonstrated. The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP). METHODS: A cross-sectional study of patients with chronic rhinosinusitis (CRS), with or without nasal polyposis, managed with daily nasal budesonide via MAD was conducted at a tertiary rhinology center. Patients using systemic steroids within 3 months of assessment were excluded. HPAA impact was assessed using the cosyntropin stimulation test for adrenal function and a survey of relevant symptomatology. Patients also underwent tonometry to assess for elevated IOP potentially related to corticosteroid use. RESULTS: A total of 100 CRS patients were recruited with a mean budesonide treatment duration of 23.5 months (range, 6-37 months). Stimulated cortisol response was diminished in 3 patients (3%). No patients with adrenal suppression had relevant symptomatology. IOP was elevated in 6 patients (6%). CONCLUSION: These findings suggest that there is a risk of adrenal suppression and raised IOP associated with the long-term use of topical nasal budesonide via MAD. Otolaryngologists should consider periodic surveillance for these adverse events in this patient cohort.
dc.description.versionVersión Publicada
dc.format.extent6
dc.identifier.citationManji J, Singh G, Okpaleke C, Dadgostar A, Al-Asousi F, Amanian A, Macias-Valle L, Finkelstein A, Tacey M, Thamboo A, Javer A. Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017 May;7(5):488-493. doi: 10.1002/alr.21910
dc.identifier.urihttp://hdl.handle.net/11447/1703
dc.identifier.urihttp://dx.doi.org/10.1002/alr.21910
dc.language.isoen_US
dc.publisherJohn Wiley & Sons
dc.sourceInternational Forum of Allergy & Rhinology
dc.subjectHPA axis
dc.subjectIOP
dc.subjectbudesonide
dc.subjectchronic rhinosinusitis
dc.subjectmucosal atomization device
dc.subjectpostoperative care
dc.subjectsafety
dc.titleSafety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis
dc.typeArtículo

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis.pdf
Size:
268.29 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services